oncore manufactures stock and custom fiber optic and copper network cable assemblies, power and audio/video cables and a full line of notebook/netbook batteries.
copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Huntsman Cancer Institute Clincial Trials Disease sites may be classified into broader categories For example, colon, pancreas, and liver cancers are all classified under Gastrointestinal cancers; ovarian, uterine and endometrial cancers are classified as Gynecological; and prostate and kidney cancers are classified as Genitourinary
Version Date: 4 23 21 Protocol No. HCI IRB # 141461 Objectives Primary Objectives Primary Phase I objective: To assess the safety of OBI3424 and to determine the maximum tolerated dose (MTD) of OBI3424 in this regimen for patients with relapsed refractory Tcell acute lymphoblastic leukemia (T-ALL) T-cell lymphoblastic lymphoma (T-LBL) Primary Phase II objective: To assess the response rate [complete remission (CR) or CR with incomplete count
Version Date: 4 17 15 Protocol No. HCI IRB # 71940 Objectives To determine the maximum tolerated dose for stereotactic radiosurgery (SRS) treatment for patients with 1-5 brain metastases treated with SRS as the first line therapy for their CNS disease
Version Date: 12 2 20 Protocol No. HCI IRB # 138975 Inclusion Criteria PATIENT SELECTION, ELIGIBILITY, AND INELIGIBILTY CRITERIA: Note: Per NCI guidelines, exceptions to inclusion and exclusion criteria are not permitted For questions concerning eligibility, please contact the Statistics and Data Management Center (via the contact list on the NRG web site) Patient Selection Guidelines: Although the guidelines provided here are not inclusion
Version Date: 7 15 17 Protocol No. HCI IRB # 88405 Objectives Our over-arching study goal is to identify germline variants and biomarkers involved in risk or prognosis of hematological malignancies (HMs) Four designs provide a framework for the research: (1) genealogy-based; (2) pedigree-based; (3) case-control; and (4) case-only
Protocol No. HCI IRB # 148056 - utah-oncore. forteresearchapps. com Objectives Primary Objective(s) To evaluate recurrence-free survival (RFS) in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only Secondary Objective(s) To evaluate overall survival (OS) in participants randomized to treatment with CAPTEM compared to observation only To evaluate the
Version Date: 5 22 19 Protocol No. HCI IRB # 122217 Inclusion Criteria **HCI WILL NOT HAVE PATIENTS <18 YEARS OF AGE** Inclusion Criteria Subjects who meet the following criteria will be eligible to participate in the LTFU study: 1 All adult and pediatric subjects who received at least one GM T cells infusion in a previous Celgene sponsored or Celgene alliance partner sponsored study, and have discontinued, or completed the post-treatment
Version Date: 5 27 17 Protocol No. HCI IRB # 101380 All men seen at this Prostate Cancer Risk Clinic (as well as all HCI cancer patients, family members, and healthy volunteers) are invited to enroll in IRB #89989, Total Cancer Care IRB #89989 covers the collection of clinical data and tissue for future research The present IRB is a protocol for the use and analysis of the data tissue collected on a subset of individuals enrolled in IRB